Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07206498 | A Study to Evaluate Safety and Efficacy of WSD0922-FU Combo With Osimertinib for NSCLC(WAYWIN103) | recruiting | Phase 1 / Phase 2 | 48 | Wayshine Biopharm, Inc.INDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07250386 | A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors(PBC102) | recruiting | Phase 1 | 48 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT06332755 | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC(LB-LR1109) | recruiting | Phase 1 | 76 | LG ChemINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07232420 | A Study of BL-M24D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 33 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06283719 | Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 265 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06848699 | A Phase Ib/II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Patients With Advanced/Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 105 | Shanghai Henlius BiotechINDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07231068 | A Dose-escalation and Dose-expansion Phase I/Phase II Clinical Study of Dositinib Mesylate Tablets (90-1408) in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer With Positive EGFR Mutation | recruiting | Phase 1 / Phase 2 | 153 | Henan Genuine Biotech Co., Ltd.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05558904 | An Investigational Scan (Me-4FDG PET/CT) for the Detection of Sodium-Glucose Transport for Early Diagnosis of Lung Cancer | recruiting | Phase 1 / Phase 2 | 60 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT05244239 | Palliative Radiotherapy With Lurbinectedin in Patients With Extensive Stage Small Cell Lung Cancer | recruiting | Phase 1 | 22 | Emory UniversityOTHER | 1 | Oct 31, 2025 | clinicaltrials |
| NCT06228326 | A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs(KYANITE-1) | recruiting | Phase 1 / Phase 2 | 250 | Krystal Biotech, Inc.INDUSTRY | 1 | Oct 24, 2025 | clinicaltrials |
| NCT01720836 | Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 30 | Olivera FinnOTHER | 1 | Oct 21, 2025 | clinicaltrials |
| NCT06784193 | Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 180 | Olema Pharmaceuticals, Inc.INDUSTRY | 2 | Oct 10, 2025 | clinicaltrials |
| NCT04370587 | A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 30 | ImmVira Pharma Co. LtdINDUSTRY | 2 | Oct 8, 2025 | clinicaltrials |
| NCT05296564 | Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers | recruiting | Phase 1 / Phase 2 | 3 | Hadassah Medical OrganizationOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT06448572 | EXL01 in Combination With Nivolumab for Advanced NSCLC Refractory to Immunotherapy.(EXLIBRIS) | recruiting | Phase 1 / Phase 2 | 21 | University Hospital, LilleOTHER | 1 | Sep 25, 2025 | clinicaltrials |
| NCT06805825 | A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit | recruiting | Phase 1 | 67 | Novelty Nobility, Inc.INDUSTRY | 1 | Sep 23, 2025 | clinicaltrials |
| NCT06210815 | A Study of HLX42 in Advanced/Metastatic Solid Tumors | recruiting | Phase 1 | 102 | Shanghai Henlius BiotechINDUSTRY | 1 | Sep 22, 2025 | clinicaltrials |
| NCT06505824 | A Study of BL-M14D1 in Patients With Locally Advanced or Metastatic Small Cell Lung Cancer, Neuroendocrine Tumors and Other Solid Tumors | recruiting | Phase 1 | 22 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 18, 2025 | clinicaltrials |
| NCT07169994 | A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 414 | MediLink Therapeutics (Suzhou) Co., Ltd.INDUSTRY | 1 | Sep 12, 2025 | clinicaltrials |
| NCT05107674 | A Study of NX-1607 in Adults With Advanced Malignancies | recruiting | Phase 1 | 345 | Nurix Therapeutics, Inc.INDUSTRY | 2 | Sep 9, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT07056556 | A Study of BL-M09D1 in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer and Other Solid Tumors | recruiting | Phase 1 | 31 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT07130916 | A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer | recruiting | Phase 1 | 20 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 3 | Aug 19, 2025 | clinicaltrials |
| NCT04429542 | Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | recruiting | Phase 1 | 292 | Bicara TherapeuticsINDUSTRY | 3 | Aug 15, 2025 | clinicaltrials |
| NCT06861543 | The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)(TMT101-01) | recruiting | Phase 1 | 18 | Peking Union Medical College HospitalOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT06896422 | Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC | recruiting | Phase 1 | 80 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT06592638 | A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer | recruiting | Phase 1 | 30 | Suzhou Zelgen Biopharmaceuticals Co.,LtdINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT07096882 | SDTM001 Injection as Adjuvant Therapy for NSCLC Patients After Radical Surgical Resection | recruiting | Phase 1 | 22 | Cytocraft Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 31, 2025 | clinicaltrials |
| NCT05086692 | A Beta-only IL-2 ImmunoTherapY Study(ABILITY-1) | recruiting | Phase 1 / Phase 2 | 115 | Medicenna Therapeutics, Inc.INDUSTRY | 7 | Jul 9, 2025 | clinicaltrials |
| NCT06773507 | Phase I Study of BC008-1A Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 80 | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT03093688 | Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor | recruiting | Phase 1 / Phase 2 | 40 | Shanghai Public Health Clinical CenterOTHER_GOV | 1 | Jul 2, 2025 | clinicaltrials |
| NCT06946927 | A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation | recruiting | Phase 1 | 72 | JemincareINDUSTRY | 1 | Jul 1, 2025 | clinicaltrials |
| NCT06596915 | Safety and Efficacy of BA1302 in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 167 | Shandong Boan Biotechnology Co., LtdINDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06969612 | A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC | recruiting | Phase 1 | 21 | Peking University Cancer Hospital & InstituteOTHER | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06902350 | Safety, Pharmacokinetics and Preliminary Efficacy of CS231295 in Advanced Solid Tumors | recruiting | Phase 1 | 102 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | May 25, 2025 | clinicaltrials |
| NCT06343064 | Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI(KYLIN-1) | recruiting | Phase 1 / Phase 2 | 156 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT06972576 | Clinical Study of Combined EphA2-targeted CAR-DC and CAR-T Cell Therapy for Non-small Cell Lung Cancer | recruiting | Phase 1 | 18 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06970795 | A Study of SYS6040 for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 | 180 | CSPC Megalith Biopharmaceutical Co.,Ltd.INDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT05994131 | IN10018 Combination Therapy in Advanced EGFR Mutation-positive NSCLC | recruiting | Phase 1 / Phase 2 | 110 | InxMed (Shanghai) Co., Ltd.INDUSTRY | 1 | Apr 30, 2025 | clinicaltrials |
| NCT06046495 | A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer | recruiting | Phase 1 | 81 | Avistone Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06754930 | A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC | recruiting | Phase 1 / Phase 2 | 400 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06926413 | A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC | recruiting | Phase 1 | 20 | Jiangsu Hansoh Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 13, 2025 | clinicaltrials |
| NCT06621563 | Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors(HS-20117) | recruiting | Phase 1 | 780 | Hansoh BioMedical R&D CompanyINDUSTRY | 1 | Apr 9, 2025 | clinicaltrials |
| NCT05473156 | A Study to Investigate the Safety, Pharmacokinetics, and Clinical Activity of AP203 in Patients with Locally Advanced or Metastatic Solid Tumors, and Expansion to Selected Malignancies(APT-CUBE) | recruiting | Phase 1 / Phase 2 | 168 | AP Biosciences Inc.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06896890 | Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer | recruiting | Phase 1 / Phase 2 | 32 | Inhatarget TherapeuticsINDUSTRY | 3 | Mar 26, 2025 | clinicaltrials |
| NCT06069570 | Safety Study for a Gamma Delta T Cell Product Used With Low Dose Radiotherapy in Patients With Locally Advanced or Metastatic NSCLC or Solid Tumors With Bone Metastases | recruiting | Phase 1 | 48 | Kiromic BioPharma Inc.INDUSTRY | 1 | Mar 5, 2025 | clinicaltrials |
| NCT04147078 | Personalized DC Vaccine for Postoperative Cancer | recruiting | Phase 1 | 80 | Sichuan UniversityOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT06484816 | TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies | recruiting | Phase 1 | 90 | Shenzhen TargetRx Co., Ltd.INDUSTRY | 1 | Feb 24, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Dec 3, 2025source: clinicaltrials